EGFR and cancer: Anti‐cancer drugs targeting specific genomic alterations, such as the epidermal growth factor receptor (EGFR),3 human epidermal growth factor receptor‐related 2 (HER2),4 and v‐raf murine sarcoma viral oncogene homolog B1 (BRAF),5 have improved survival and disease response in patients with various malignancies.